The number of proliferating cells and mean blood vessels and the percentage of CD11b+Gr-1+ MDSCs in tumor tissues were also significantly reduced with anti-γδ TCR or anti-NKG2D mAb administration (Supplementary Figures  2(a)–2(c)). This evidence concerns the gene KLRK1 and neoplasm.